The Replenza supplements are coming to market just as the makers of Ozempic have developed a pill that can cause weight loss of up to 13% in three months, suggesting that dropping pounds and drooping faces will continue to be a problem that needs addressing.
Studies have shown that GLP-1R agonists are also able to reduce myocardial infarction, stroke and heart failure (Solini et al., 2023
Let's hope Teva comes up with a cool name for this one #obesity #diabetes #biosimilar #generic #biotechindustry #pharma Thanks for sharing, it will be interesting to see if cost is prioritized over efficacy and convenience, and how Teva positions its daily Saxenda generic in a market dominated by next-gen weekly GLP-1s
The resulting accumulation of fat in hepatocytes makes the liver susceptible to inflammatory mediators and/or toxic agents, leading to progressive injury, which progresses to alcoholic steatohepatitis (ASH), fibrosis, cirrhosis, and cancer (Li et al., 2024
The net result is a reduction in systemic endotoxin burden and inflammatory tone